Home/Pipeline/CC-99712 (BCMA ADC)

CC-99712 (BCMA ADC)

Multiple Myeloma

Phase 1Active

Key Facts

Indication

Multiple Myeloma

Phase

Phase 1

Status

Active

Company

Sutro Biopharma

About Sutro Biopharma

Sutro Biopharma is advancing a differentiated ADC platform and pipeline with the goal of redefining cancer therapy. Its core XpressCF® technology enables the cell-free synthesis and site-specific conjugation of proteins, allowing for the creation of homogeneous ADCs with optimized properties. The company's strategy combines internal development of lead assets, like luveltamab tazevibulin, with strategic platform partnerships to validate its technology. Despite a challenging market valuation, Sutro's clinical progress and platform capabilities position it as a unique player in the competitive ADC landscape.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active
Sequesta™	ID4Pharma	Pre-clinical	Active
Myeloma Consortium	Criterium	Unknown	Active
GPRC5D x CD3 TCE	Integral Molecular	Preclinical	Available for License
RORA-Tscm CAR-T	RORABio	Pre-clinical	Active